Tag: Pakistan

Explore all our news . .

Recent Posts

FNA DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Paragon 28, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important November 29 Deadline in Securities Class Action First Filed by the Firm – FNA

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Paragon 28, Inc. (NYSE: FNA) between May 5, 2023 and September 20, 2024, both dates inclusive (the “Class Period”), and those who purchased Paragon 28 call

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages iLearningEngines, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AILE

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iLearningEngines, Inc. (NASDAQ: AILE) between April 22, 2024 and August 28, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline.

BMBL DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Bumble Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – BMBL

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bumble Inc. (NASDAQ: BMBL) between November 7, 2023 and August 7, 2024, both dates inclusive (the “Class Period”), of the important November 25, 2024 lead plaintiff deadline.

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 20, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery